Sars-CoV2 infection in pregnant women with multiple sclerosis

Aprea M. G., Schiavetti I., Portaccio E., Ballerini C., Battaglia M. A., Bergamaschi R., ...More

Multiple Sclerosis Journal, vol.29, no.9, pp.1090-1098, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 9
  • Publication Date: 2023
  • Doi Number: 10.1177/13524585231176174
  • Journal Name: Multiple Sclerosis Journal
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, EMBASE, MEDLINE
  • Page Numbers: pp.1090-1098
  • Keywords: COVID-19, COVID-19 outcomes, Multiple sclerosis, pregnancy, risk factors, SARS-CoV-2 infection
  • Hacettepe University Affiliated: Yes


Background: In the general population, maternal SARS-CoV-2 infection during pregnancy is associated with worse maternal outcomes; however, only one study so far has evaluated COVID-19 clinical outcomes in pregnant and postpartum women with multiple sclerosis, showing no higher risk for poor COVID-19 outcomes in these patients. Objective: In this multicenter study, we aimed to evaluate COVID-19 clinical outcomes in pregnant patients with multiple sclerosis. Methods: We recruited 85 pregnant patients with multiple sclerosis who contracted COVID-19 after conception and were prospectively followed-up in Italian and Turkish Centers, in the period 2020-2022. A control group of 1354 women was extracted from the database of the Multiple Sclerosis and COVID-19 (MuSC-19). Univariate and subsequent logistic regression models were fitted to search for risk factors associated with severe COVID-19 course (at least one outcome among hospitalization, intensive care unit [ICU] admission and death). Results: In the multivariable analysis, independent predictors of severe COVID-19 were age, body mass index ⩾ 30, treatment with anti-CD20 and recent use of methylprednisolone. Vaccination before infection was a protective factor. Vaccination before infection was a protective factor. Pregnancy was not a risk nor a protective factor for severe COVID-19 course. Conclusion: Our data show no significant increase of severe COVID-19 outcomes in patients with multiple sclerosis who contracted the infection during pregnancy.